How do you treat metastatic RCC with fumarate hydratase mutation (Hereditary Leiomyomatosis and RCC [HLRCC])?

Topics: Genitourinary Cancers • Medical Oncology • Renal Cell Carcinoma

There was an abstract in European J of Cancer (Srinivasan R, 2014:50: S6, P8) showing a good response rate with Bevacizumab and Erlotinib. Would you use this regimen with new generation of potent TKIs and check point inhibitors?

Answer from: Medical Oncologist at Academic Institution

HLRCC and Fumarate Hydratase deficient RCC is a molecularly defined entity that was previously included in papillary type 2 RCC. The data for the efficacy of IO/VEGF combinations is limited; however, there is interest in investigating their efficacy. There are few prospective studies of anti-PD...

Comments

Medical Oncologist at UPMC Hillman Cancer Center
There have been single case reports of response to...

Related Questions